Familial Hypercholesterolemia Interpretive Comment - Nudging to Detection.
Launched by ODENSE UNIVERSITY HOSPITAL · Nov 10, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Familial Hypercholesterolemia Interpretive Comment - Nudging to Detection," is focused on improving the diagnosis of familial hypercholesterolemia, a common inherited condition that leads to high cholesterol levels. In Denmark, many people with this condition remain undiagnosed, with only 15% of potential patients identified. The study aims to see if adding a special comment to blood test results that show high levels of LDL cholesterol (often referred to as "bad" cholesterol) can encourage doctors to refer more patients to specialized lipid clinics. The trial will run for a year and will gradually implement this comment across different laboratories in Southern Denmark.
To participate, patients must be referred to the lipid clinics and meet certain criteria based on their cholesterol levels: those under 40 should have an LDL-C level below 4 mmol/L, while those over 40 should have it above 5 mmol/L. Some individuals will not be eligible, such as pregnant women or those with certain health conditions affecting cholesterol levels. Participants can expect to help researchers understand whether this new approach can lead to more accurate diagnoses and better care for people with familial hypercholesterolemia.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All referred patients to the lipid clinics of Southern Denmark
- • LDL-C \< 4 mmol/L in persons under the age of 40.
- • LDL-C \> 5 mmol/L in persons over the age of 40.
- Exclusion Criteria:
- • Pregnancy and Secondary dyslipidemia
- • Dysregulated diabetes. Hba1C \< 48
- • Dysregulated hypothyreosis. Elevated TSH.
- • Kombined hyperlipidiemia TG \> 4 mmol/L
- • Nefrotic syndrome: proteinuria \> 3 g/L and s-albumin \< 30 g/l
- • Cholestasis (alcalic fosfatase \> 105 U/L and GGT \> 55 U/L) 14 days prior to LDL-C measuring
- • Pharmacological induced hyperlipidimia
About Odense University Hospital
Odense University Hospital is a leading academic medical center located in Denmark, dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital is committed to enhancing patient outcomes and fostering collaboration among multidisciplinary teams. With a focus on translating scientific discoveries into practical applications, Odense University Hospital leverages its state-of-the-art facilities and expertise to conduct rigorous trials across various medical fields, ensuring adherence to the highest ethical and regulatory standards. Through these efforts, the hospital aims to contribute significantly to the global body of medical knowledge and improve the quality of care for patients both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Odense, Funen, Denmark
Odense C, , Denmark
Patients applied
Trial Officials
Finn Lund Henriksen, Ph.d.
Principal Investigator
Departement of Cardiology, Odense University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials